Today: 21 May 2026
Metlen share price rebounds in London after profit warning; investors brace for March 31 results
9 February 2026
2 mins read

Metlen share price rebounds in London after profit warning; investors brace for March 31 results

London, Feb 9, 2026, 10:24 GMT — Regular session

Metlen Energy & Metals PLC (MTLN.L) bounced roughly 4.8% higher in London Monday, clawing back some ground after last week’s drop. By mid-morning, the stock was trading at 37.50 euros, after slipping to 35.20 euros earlier—marking a fresh 52-week low. Market cap sits around €5.36 billion.

Traders are scrambling to assess the financial hit after the group slashed its 2025 earnings forecast and pointed to new operational problems in its energy projects arm. On Friday, Metlen cut its 2025 EBITDA guidance by roughly 25% versus its previous goal, citing cost overruns at M Power Projects and delays in closing some renewables asset-rotation transactions.

The stock plunged nearly 20% Friday following the warning, ranking among the FTSE 100’s worst performers that day. Monday has brought only a modest recovery, clawing back just a fraction of the loss.

Investors like EBITDA because it leaves out taxes, financing costs, and depreciation—a non-cash expense—so they use it as a quick gauge of operating cash flow.

Metlen, which runs aluminium and power businesses out of Athens and London, flagged fresh cost overruns and more delays at its M Power Projects division—it’s not the first time, with earlier trouble coming from the UK’s Protos venture. September’s update put 2025 EBITDA above 1 billion euros, while for 2024, the company reported EBITDA of 1.08 billion euros, according to Alliance News.

Asset sales are playing a key role here: Metlen’s been cycling projects out, but three deals—covering the UK, Spain, and Australia—are now pushed out past end-2025. The UK solar package? That changed hands on Feb. 4, with Schroders Greencoat picking it up. “Another important milestone” for their asset-rotation push, said Metlen’s renewables head Nikos Papapetrou. Over at Schroders Greencoat, portfolio manager Duncan Hale called the buy a “significant milestone” for UK pension savers. Metlen Energy & Metals

Metlen shifted its main listing to London last autumn, joining the FTSE UK indices as one of the first euro-denominated names—a move that’s lifted daily liquidity but also leaves shares more exposed to sharp drops on negative headlines. The company described its core business as “robust” and said 2026 was “started well”, despite project overruns prompting a reduction in its top-line target. Sharecast

Metlen pointed to a liquidity position topping 4 billion euros as of end-2025, while adjusted net debt sits near 2 billion euros. The company also stuck to its earlier medium-term EBITDA guidance—still calling for a range between 1.9 billion and 2.08 billion euros.

Yet buyers are coming in while the audit remains unfinished, with additional cost problems possible as these projects wrap up. If renewables deals stall again, or if metals and power markets take a bigger hit, shares likely stay weighed down.

Next up: Metlen’s preliminary full-year 2025 figures and its conference call, both set for March 31. Investors are looking for more detail on M Power Projects and what’s coming in renewables. The company has its annual report slated for April 9, and a trading update for the first three months of 2026 lined up for May 7.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy
Previous Story

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Nvidia’s Jensen Huang calls Meta AI’s profit pioneer as spending fears swirl
Next Story

Nvidia’s Jensen Huang calls Meta AI’s profit pioneer as spending fears swirl

Go toTop